MoneyShow's Best Investment Ideas For 2026: Part 1 [Seeking Alpha]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Seeking Alpha
This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 1 of this series includes AbbVie, Alexandria Real Estate Equities, Arbor Realty Trust, Archer Aviation, and Ares Management Corp., among others. We Are/DigitalVision via Getty Images MoneyShow's top contributing analysts, strategists, and newsletter editors share their investment recommendations for the year ahead. AbbVie Inc. By Tom Hutchinson, Editor, Cabot Dividend Investor AbbVie Inc. ABBV is a US-based biopharmaceutical This article was written by Quick Insights ABBV replaced peak Humira revenues with Skyrizi and Rinvoq, guiding for $31B in 2027 and $40B by 2029, with 20 drugs in phase III trials. ARE's specialized life science campuses, stabilized leasing, strong credit metrics, and a recent dividend cut reinforce its balance sheet, positioning it for re-rating
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Emmecell Appoints Ramin Valian as Chief Executive Officer to Advance Magnetic Cell Delivery Platform [Yahoo! Finance]Yahoo! Finance
- AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)PR Newswire
- Five Takeaways From The 2026 J.P. Morgan Healthcare Conference [Forbes]Forbes
- AbbVie Inc.'s (NYSE:ABBV) institutional investors lost 3.3% last week but have benefitted from longer-term gains [Yahoo! Finance]Yahoo! Finance
- AbbVie (NYSE:ABBV) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.MarketBeat
ABBV
Earnings
- 10/31/25 - Beat
ABBV
Sec Filings
- 1/7/26 - Form 8-K
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- ABBV's page on the SEC website